Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study - Liu, X; Zhou, H; Hu, Y (Lancet Haematol, 2023)